Fig. 5
From: Kinase inhibitor pulldown assay (KiP) for clinical proteomics
KiP clusters breast cancer patient samples by subtype by quantifying kinases. KiP-PRM clusters breast cancer patient samples by intrinsic subtype, identifies subgroups within subtypes, and partially clusters resistant patients within subtype. 37 patient samples from a HER2 + cohort and a luminal cohort were processed with the KiP assay and analyzed by PRM. HER2 is highly enriched in the HER2 + cohort, and luminal associated kinases such as CDK4 were elevated in the Luminal cohort. ypCR yes pathological complete response, LowerProlif Lower Proliferation, not a complete response, CS Absolute Score CIBERSORT ABSOLUTE Score